AskVantage

Biotech and enhanced humans

Promising anti-aging treatment that extends lifespans by a third heads for human trials

Anti-aging research has been going through a renaissance over the past few years, and now scientists plan on starting the first human trials

Key takeaways

  • One of the constant areas of focus though throughout all of the research has been in the field of senescent cells, or to put it another way, the cells that play a pathological role in age related diseases.
  • The research, which has been published in Cell, involved administering the peptide to genetically engineered fast-aging mice three times a week for over 10 months.
  • Within 10 days of starting the treatment patches of missing fur reappeared on their coats, and after three weeks the mice receiving the treatment had the ability to run twice as far as mice that hadn't received the treatment.
Cite or link to this article

Griffin, M. (2017) 'Promising anti-aging treatment that extends lifespans by a third heads for human trials', 311 Institute, 31 March. Available at: https://www.311institute.com/promising-anti-aging-treatment-that-extends-lifespans-by-a-third-heads-for-human-trials/ (Accessed: 1 October 2026).

Over the past few years there has been more investment, and more interest in anti-ageing technologies, and while some scientists have decided to classify it as a disease there have been some notable, albeit nascent breakthroughs such as late last year when researchers reversed ageing in mice, discovered the genes responsible for ageing, and put embryos into suspended animation.

As you can see, at the moment there’s no single silver bullet, but that’s often how early stage research plays out. One of the constant areas of focus though throughout all of the research has been in the field of senescent cells, or to put it another way, the cells that play a pathological role in age related diseases.

Now a team of scientists at Erasmus University Medical Center (EUMC) in the Netherlands has discovered a peptide that targets these cells to reverse the symptoms of aging in mice. The treatment restored missing fur, improved kidney function and fitness in mice genetically engineered to rapidly age.

In the past scientists have been trying to develop new treatments that can kill senescent cells without damaging healthy cells, and in 2015, a team at The Scripps Research Institute discovered two compounds selectively targeted specific groups of senescent cells. And in 2016, researchers at the Mayo Clinic trialled a compound that eliminated senescent cells in mice, resulting in an extension of their average lifespans of between 17 and 35 percent.

The peptide that EUMC have identified causes senescent cells to go through a process known as Apoptosis, or programmed cell death, and the therapy works by blocking the communication of a protein called FOXO4 with another protein, p53. It’s believed that the interaction of these two proteins is what causes senescence in cells and when that communication is blocked the senescent cells self destruct.

What makes this an important discovery is the fact that the peptide only causes cell death in senescent cells, and not healthy cells, and that’s a major breakthrough.

"FOXO4 is barely expressed in non-senescent cells, so that makes the peptide interesting as the FOXO4-p53 interaction is especially relevant to senescent cells, but not normal cells," says Peter de Keizer, one of the senior researchers involved in the project.

The research, which has been published in Cell, involved administering the peptide to genetically engineered fast-aging mice three times a week for over 10 months. Over the course of the treatment, the researchers identified different effects manifesting in the mice. Within 10 days of starting the treatment patches of missing fur reappeared on their coats, and after three weeks the mice receiving the treatment had the ability to run twice as far as mice that hadn't received the treatment.

Biomarkers indicating healthy kidney function were also seen after one month of treatment, signalling an improvement in their renal function, and, with almost a year of regular infusions under their belts, the team failed to identify any obvious negative side effects of the treatment.

Now that the treatment appears to work, without side effects the team are now gearing up to start human trials but a lot of questions still remain, and the team don’t know if they will see the same results in people. That said though, so far, the research has shown great promise so who knows, one day soon, when you celebrate your next birthday, you might also be celebrating getting younger – and wouldn’t that be something to get your head around.

FAQ

Why does this matter?

Anti-aging research has been going through a renaissance over the past few years, and now scientists plan on starting the first human trials

Matthew Griffin

About the author

Matthew Griffin Founder, 311 Institute

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."

Read full bio

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.

An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.

As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.

What future do you need to see?

Choose one to get started on biotech and enhanced humans and the future of your organisation.

Where should Matthew reply?

Takes 30 seconds. No obligation. Matthew replies quickly. Privacy

Tag Cloud

Starburst opens that technology on the interactive 311 Starburst.

Sources and further reading

  1. Senescence en.wikipedia.org
  2. Erasmus University Medical Center erasmusmc.nl
  3. Peptide en.wikipedia.org
  4. FOXO4 en.wikipedia.org
  5. p53 en.wikipedia.org

Source: first published by the 311 Institute on 31 March 2017. Cite as: Griffin, M. (2017). Promising anti-aging treatment that extends lifespans by a third heads for human trials. 311 Institute. https://www.311institute.com/promising-anti-aging-treatment-that-extends-lifespans-by-a-third-heads-for-human-trials/

You are welcome to quote this article with credit and a link to the original.

Book a Keynote